Summary:
A Randomized, Double-Blind, Placebo-Controlled, Phase 2b, Multicenter Study to Evaluate the Safety, Efficacy, and Tolerability of SNA-120 (Pegcantratinib Ointment) in Subjects with Pruritis Associated with Psoriasis Vulgaris.
Qualified Participants Must:
• Be12 years of age or older
•
IGA mild-moderate
•
BSA 1-15%
•
Have had Psoriasis for 6 months
•
Have stable itch for 6 weeks
•
Have moderate itch at screening
Qualified Participants May Receive:
12-week treatment, 2-week f/u
topical ointment
0.5%, 0.05%, vs placebo 1:1:1